Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antitumor activity of AZD0754, a dnTGFβRII-armored, STEAP2-targeted CAR-T cell therapy, in prostate cancer.
Zanvit P, van Dyk D, Fazenbaker C, McGlinchey K, Luo W, Pezold JM, Meekin J, Chang CY, Carrasco RA, Breen S, Cheung CS, Endlich-Frazier A, Clark B, Chu NJ, Vantellini A, Martin PL, Hoover CE, Riley K, Sweet SM, Chain D, Kim YJ, Tu E, Harder N, Phipps S, Damschroder M, Gilbreth RN, Cobbold M, Moody G, Bosco EE. Zanvit P, et al. Among authors: mcglinchey k. J Clin Invest. 2023 Nov 15;133(22):e169655. doi: 10.1172/JCI169655. J Clin Invest. 2023. PMID: 37966111 Free PMC article.
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
Tu E, McGlinchey K, Wang J, Martin P, Ching SL, Floc'h N, Kurasawa J, Starrett JH, Lazdun Y, Wetzel L, Nuttall B, Ng FS, Coffman KT, Smith PD, Politi K, Cooper ZA, Streicher K. Tu E, et al. Among authors: mcglinchey k. JCI Insight. 2022 Feb 8;7(3):e142843. doi: 10.1172/jci.insight.142843. JCI Insight. 2022. PMID: 35132961 Free PMC article.
Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A, Chen C, Strout P, Mulgrew K, McGlinchey K, Fleming R, Bezabeh B, Meekin J, Stewart D, Kennedy M, Martin P, Buchanan A, Dimasi N, Michelotti E, Hollingsworth R. Rios-Doria J, et al. Among authors: mcglinchey k. Cancer Res. 2017 May 15;77(10):2686-2698. doi: 10.1158/0008-5472.CAN-16-2854. Epub 2017 Mar 10. Cancer Res. 2017. PMID: 28283653
Targeting CD73 in the tumor microenvironment with MEDI9447.
Hay CM, Sult E, Huang Q, Mulgrew K, Fuhrmann SR, McGlinchey KA, Hammond SA, Rothstein R, Rios-Doria J, Poon E, Holoweckyj N, Durham NM, Leow CC, Diedrich G, Damschroder M, Herbst R, Hollingsworth RE, Sachsenmeier KF. Hay CM, et al. Among authors: mcglinchey ka. Oncoimmunology. 2016 Jul 11;5(8):e1208875. doi: 10.1080/2162402X.2016.1208875. eCollection 2016 Aug. Oncoimmunology. 2016. PMID: 27622077 Free PMC article.
Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD, Augé C, Morris C, Kentner S, Mulgrew K, McGlinchey K, Hair J, Hanabuchi S, Du Q, Damschroder M, Feng H, Eck S, Buss N, de Haan L, Pierce AJ, Park H, Sylwester A, Axthelm MK, Picker L, Morris NP, Weinberg A, Hammond SA. Oberst MD, et al. Among authors: mcglinchey k. Mol Cancer Ther. 2018 May;17(5):1024-1038. doi: 10.1158/1535-7163.MCT-17-0200. Epub 2018 Mar 15. Mol Cancer Ther. 2018. PMID: 29545330 Free PMC article.
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Schofield DJ, Percival-Alwyn J, Rytelewski M, Hood J, Rothstein R, Wetzel L, McGlinchey K, Adjei G, Watkins A, Machiesky L, Chen W, Andrews J, Groves M, Morrow M, Stewart RA, Leinster A, Wilkinson RW, Hammond SA, Luheshi N, Dobson C, Oberst M. Schofield DJ, et al. Among authors: mcglinchey k. MAbs. 2021 Jan-Dec;13(1):1857100. doi: 10.1080/19420862.2020.1857100. MAbs. 2021. PMID: 33397194 Free PMC article.
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity.
Harper J, Burke S, Travers J, Rath N, Leinster A, Navarro C, Franks R, Leyland R, Mulgrew K, McGlinchey K, Brown L, Dovedi SJ, Koopmann JO, Durham NM, Cheng X, Jin H, Eyles J, Wilkinson RW, Carroll D. Harper J, et al. Among authors: mcglinchey k. Mol Cancer Ther. 2021 Sep;20(9):1723-1734. doi: 10.1158/1535-7163.MCT-20-0902. Epub 2021 Jun 17. Mol Cancer Ther. 2021. PMID: 34224361 Free PMC article.
A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist.
Leyland R, Watkins A, Mulgrew KA, Holoweckyj N, Bamber L, Tigue NJ, Offer E, Andrews J, Yan L, Mullins S, Oberst MD, Coates Ulrichsen J, Leinster DA, McGlinchey K, Young L, Morrow M, Hammond SA, Mallinder P, Herath A, Leow CC, Wilkinson RW, Stewart R. Leyland R, et al. Among authors: mcglinchey k. Clin Cancer Res. 2017 Jul 1;23(13):3416-3427. doi: 10.1158/1078-0432.CCR-16-2000. Epub 2017 Jan 9. Clin Cancer Res. 2017. PMID: 28069723
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire.
Swanson PA 2nd, Padilla M, Hoyland W, McGlinchey K, Fields PA, Bibi S, Faust SN, McDermott AB, Lambe T, Pollard AJ, Durham NM, Kelly EJ; AstraZeneca/Oxford/VRC Study Group. Swanson PA 2nd, et al. Among authors: mcglinchey k. Sci Transl Med. 2021 Nov 17;13(620):eabj7211. doi: 10.1126/scitranslmed.abj7211. Epub 2021 Nov 17. Sci Transl Med. 2021. PMID: 34591596 Free PMC article.
23 results